Home › Liver Cancer (Hepatocellular Carcinoma) › Illinois › Chicago
Liver Cancer (Hepatocellular Carcinoma) clinical trials in Chicago, IL
16 studies for Liver Cancer (Hepatocellular Carcinoma) are looking for participants at sites in and around Chicago (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RecruitingPhase 1
- Exelixis Clinical Site #26, Chicago
National Liver Cancer Screening Trial
RecruitingPhase 4
- Northwestern University, Chicago
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
RecruitingPhase 1/2
- Local Institution - 0107, Chicago
Defining the Ablative Dose for Y-90 TARE
RecruitingPhase 2
- Northwestern University, Chicago
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
RecruitingObservational study
- RUSH University Medical Center, Chicago
- University of Chicago, Chicago
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
RecruitingPhase 3
- Research Site, Chicago
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RecruitingPhase 1/2
- Lurie Children's Hospital-Chicago, Chicago
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
RecruitingPhase 3
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
RecruitingPhase 2
- University of Chicago Comprehensive Cancer Center, Chicago
DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.
RecruitingObservational study
- Rush University Medical Center, Chicago
Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer
RecruitingPhase 1/2
- Northwestern University, Chicago
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
RecruitingPhase 1
- Clinical Trial Site, Chicago
Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
RecruitingPhase 2
- Northwestern University, Chicago
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
RecruitingPhase 4
- University of Chicago Medical Center, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Chicago
The Dragon PLC Trial (DRAGON-PLC)
Recruiting
- Rush University Medical Center, Chicago
Liver Cancer (Hepatocellular Carcinoma) trials in other cities
- Houston, TX31 studies
- New York City, NY24 studies
- Dallas, TX19 studies
- Los Angeles, CA19 studies
- Boston, MA18 studies
- Cleveland, OH18 studies
- Philadelphia, PA16 studies
- Pittsburgh, PA15 studies
- San Francisco, CA14 studies
- Orange, CA14 studies
- Jacksonville, FL14 studies
- San Antonio, TX13 studies
Other studies in Chicago
- Non-Small Cell Lung Cancer61 studies
- Breast Cancer59 studies
- Cancer (all types)51 studies
- Metastatic Cancer45 studies
- Prostate Cancer45 studies
- Lung Cancer41 studies
- Obesity41 studies
- Ovarian Cancer36 studies
- Colorectal Cancer34 studies
- Stroke34 studies
- Heart Failure31 studies
- Overweight29 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.